WHWK

#3413
Whitehawk Therapeutics, Inc. - Common Stock
4.6 3 USD
+0.02%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
4.63
4.63
Intervallo Annuale
2.94
5.50
Variazione giornaliera
+1.98%
Variazione Mensile
+19.33%
Variazione di 6 mesi
+46.06%
Variazione Annuale
+53.82%
Chiusura Precedente
4.5 4
Open
4.6 3
Minimo
4.6 3
Massimo
4.6 3
Volume
24
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Whitehawk Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Whitehawk Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Whitehawk Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Whitehawk Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Whitehawk Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Whitehawk Therapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Whitehawk Therapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Whitehawk Therapeutics, Inc. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
Whitehawk Therapeutics, Inc. annual report, FY2025
10-K
Current report, Q4 FY2025
Whitehawk Therapeutics, Inc. current report, Q4 FY2025
8-K

Whitehawk Therapeutics, Inc. current report, Q1 FY2025

Full document

Business Context and Reporting Period

Whitehawk Therapeutics, Inc. (WHWK) filed a Current Report on Form 8-K dated March 25, 2025. The filing reports the completion of a significant asset disposition involving the sale of a subsidiary.

Key Financial Metrics

  • Cash Proceeds: The Company received a cash payment of $102.4 million upon closing the transaction.
  • Transaction Type: Sale of 100% of the outstanding shares of capital stock of Aadi Subsidiary, Inc.
  • Counterparties: KAKEN INVESTMENTS INC., KAKEN PHARMACEUTICAL CO., LTD, and Aadi Subsidiary, Inc.
  • Other Metrics: The filing text does not provide clear values for revenue, profit, operating cash flow, margins, debt, or liquidity ratios for the reporting period.

Material Changes

The primary material change is the divestiture of Aadi Subsidiary, Inc., finalized on March 25, 2025, pursuant to a Stock Purchase Agreement originally entered into on December 19, 2024. The transaction resulted in an immediate cash inflow of $102.4 million, subject to applicable purchase price adjustments.

Guidance, Outlook, and Risks

  • Pro Forma Information: The Company intends to file required pro forma financial information as an amendment to this report within four business days of the closing.
  • Management Commentary: No specific forward-looking guidance or management commentary regarding future operations is included in this specific filing text.
  • Risks and Contingencies: The filing references the Stock Purchase Agreement for complete terms but does not detail specific risks or contingencies beyond the standard incorporation by reference.

Investor Verification Checklist

  • Verify the final purchase price adjustments applied to the $102.4 million base payment.
  • Review the upcoming amendment to this 8-K for pro forma financial information to assess the impact on the balance sheet.
  • Examine the Stock Purchase Agreement (Exhibit 2.1) for any retained liabilities or earn-out provisions.
  • Confirm the strategic rationale for the divestiture in subsequent press releases or earnings calls.